Antigenics Inc. (New York)'s QS-21 Stimulon(R) Adjuvant Enters Phase 3 Clinical Trial of GlaxoSmithKline's Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced that GlaxoSmithKline (GSK) has launched a Phase 3 clinical trial evaluating its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in non-small cell lung cancer (NSCLC) – the largest trial ever conducted in lung cancer treatment. GSK’s MAGE-A3 ASCI is delivered as a purified recombinant MAGE-A3 protein combined with GSK’s proprietary adjuvant system containing Antigenics’ QS-21 Stimulon® adjuvant, for which Antigenics will receive future milestone payments and product royalties upon successful development and commercialization. According to the World Health Organization (WHO), more than 1.3 million new cases of lung and bronchus cancer are diagnosed each year worldwide, and approximately 35 percent to 50 percent of early NSCLC expresses the MAGE-A3 antigen.1

Back to news